Hims & Hers Health reported quarterly revenue of US$753.2 million, up 38.2% year on year, added 307,000 customers to reach 2.89 million, and raised both next-quarter revenue guidance and full-year EBITDA guidance above analyst expectations, yet its stock fell 14.6% amid ongoing regulatory and legal scrutiny of its privacy and billing practices. The company faces a Federal Trade Commission lawsuit and related class action over alleged privacy and billing issues, as well as Visa's monitoring of dispute activity, which could affect customer growth and profitability. Despite the strong results, the company's narrative projects US$4.6 billion revenue and US$241.0 million earnings by 2029, requiring 21.6% yearly revenue growth and a US$383.0 million earnings increase from -US$142.0 million today. Some analysts had already expected about US$4.3 billion revenue and US$218 million earnings by 2029, and the privacy and billing shock may reinforce a more pessimistic outlook. The company's fair value is estimated at US$31.23, an 8% upside to its current price, but other estimates suggest it might be worth 19% less.
Hims Hers Health IncReported revenue of $753.2M up 38.2% YoY and raised next-quarter revenue and full-year EBITDA guidance above analyst expectations.
Visa Inc. Class A